



11 December 2017

ASX ANNOUNCEMENT

**Appendix 3Y
Change of Director's Interest Notice**

Attached is an Appendix 3Y – Change of Director's Interest Notice in respect of changes in the relevant interests in securities held by Richard Carreon, Managing Director & CEO.

On 6 December 2017, Mr Carreon acquired 912,000 Ordinary Shares through vesting of Performance Rights and sold a total of 530,000 Ordinary Shares. The sale of the shares by Mr Carreon was required to fund an immediate US tax liability arising from the vesting and automatic exercise of the Performance Rights. The Performance Rights were granted in 2014 as part of the 2015 financial year Long Term Incentive Plan.

Following this acquisition and sale, Mr Carreon now holds 834,858 Ordinary Shares. In addition, Mr Carreon holds 14,573,827 Options and 1,732,000 Performance Rights, which are subject to various time-based and performance conditions.

**Leanne Ralph
Company Secretary**

Media Contact:

Kyahn Williamson, WE Buchan
T: +61 3 9866 4722
E: kwilliamson@we-buchan.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif. and Bloomington, Minn., and a European office in Thessaloniki, Greece, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status.

ImpediMed was the first company to receive FDA clearance in the U.S. to aid healthcare professionals to clinically assess unilateral lymphoedema of the arm and leg in women and the leg in men, for its L-Dex[®] device. In addition, ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO[™], sold in select markets globally.

For more information, visit www.impedimed.com.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: ImpediMed Limited	
ABN:	089 705 144

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Richard Carreon
Date of last notice	16 November 2017

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	05 December 2017 for vesting of Performance Rights and issue of Shares 06 December 2017 for sale of Shares
No. of securities held prior to change	14,573,327 Options 2,644,000 Performance Shares 452,858 Fully paid ordinary shares
Class	1. Performance Rights 2. Ordinary Shares
Number acquired	912,000 Ordinary Share

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number disposed	912,000 Performance Rights 530,000 Ordinary Shares
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil for the vesting of the Performance Rights \$0.87 per share for the disposal of Ordinary Shares
No. of securities held after change	14,573,327 Options 1,732,000 Performance Shares 834,858 Fully paid ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Vesting of Performance Rights and on-market trade of disposal of Ordinary Shares.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

+ See chapter 19 for defined terms.

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

Date of Notice: 11 December 2017

⁺ See chapter 19 for defined terms.